Kursinformationen (Nasdaq)
- Tagestief / Hoch-
- 52W-Tief / Hoch70,730-117,770
- Jahrestief / Hoch85,660-117,770
- Volumen Intraday
Wichtigste Eigenschaften
Termine von Biomarin Pharmaceutical Inc.
- Jul26Biomarin Pharmaceutical Inc.Q2 2023 Earnings Release
- Okt25Biomarin Pharmaceutical Inc.Q3 2023 Earnings Release
Beschreibung
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and is poised for U.S. approval in 2023.
Pivot-Points (Nasdaq)
- Pivot-HBOP - R393,948 $
- Pivot-Resist - R293,457 $
- Pivot-High - R192,733 $
- Pivotpunkt92,242 $
- Pivot-Low - S191,518 $
- Pivot-Support - S291,027 $
- Pivot-LBOP - S390,303 $
Passender Service zu Biomarin Pharmaceutical Inc.
Webinar zu Biomarin Pharmaceutical Inc.
- Datum12.06.2023
- Uhrzeit19:00 - 20:00 Uhr
- Veranstalter
BNP Paribas
Erhalte jetzt Zugriff auf konkrete Trading- und Investmentideen Deiner stock3-Experten mit stock3 Trademate.
Biomarin Pharmaceutical Inc. Kurse
Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
VK | ||||||
VK |